DrugPatentWatch Database Preview

Details for Patent: 8,017,150

« Back to Dashboard

Which drugs does patent 8,017,150 protect, and when does it expire?

Patent 8,017,150 protects SUBOXONE and is included in one NDA.

This patent has one hundred and five patent family members in thirteen countries.

Summary for Patent: 8,017,150

Title:	Polyethylene oxide-based films and drug delivery systems made therefrom
Abstract:	The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.
Inventor(s):	Yang; Robert K. (Flushing, NY), Fuisz; Richard C. (McLean, VA), Myers; Garry L. (Kingsport, TN), Fuisz; Joseph M. (Washington, DC)
Assignee:	MonoSol Rx, LLC (Portage, IN)
Application Number:	12/107,389
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,017,150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010		RX	Yes	No			Y
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012		RX	Yes	No			Y
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010		RX	Yes	No			Y
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012		RX	Yes	Yes			Y

Non-Orange Book US Patents Family Members for Patent 8,017,150

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,603,514	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
7,910,031	Process for forming an ingestible thin film with non-self-aggregating uniform heterogeneity
7,425,292	Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
8,900,498	Process for manufacturing a resulting multi-layer pharmaceutical film

International Patents Family Members for US Patent 8,017,150

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	536868
Austria	536869
Austria	553746
Australia	2002332118